10-KPeriod: FY2001

THERMO FISHER SCIENTIFIC INC. Annual Report, Year Ended Dec 29, 2001

Filed March 15, 2002For Securities:TMO

Summary

Thermo Fisher Scientific Inc. (TMO), reporting as Thermo Electron Corporation for this 2001 fiscal year filing (ending December 28, 2001), is a global technology-based instrument systems provider. The company has undergone a significant reorganization, substantially completed in early 2002, which involved taking private its public subsidiaries, selling non-core businesses exceeding $1.5 billion in revenue, and spinning off paper-recycling and medical products businesses. This strategic shift aims to simplify the corporate structure and focus on integrating operations for improved productivity and enhanced customer service through improved products, technologies, and integrated systems. The company's forward-looking strategy emphasizes internal growth, supported by investments from divested businesses, and strategic acquisitions to expand technological reach into new markets. Thermo Electron operates across three primary sectors: Life Sciences, Optical Technologies, and Measurement and Control, serving diverse markets including biotechnology, pharmaceuticals, healthcare, microelectronics, and industrial process control. The report indicates a planned focus on high-growth markets and delivering complete, integrated solutions to customers.

Key Highlights

  • 1Thermo Fisher Scientific (Thermo Electron) has completed a major reorganization, simplifying its structure by taking private subsidiaries and divesting non-core assets, a process substantially finished by February 2002.
  • 2The company's strategy is to focus on integrating operations for efficiency and customer service, alongside emphasizing internal growth funded by asset sales and pursuing strategic acquisitions.
  • 3Thermo Fisher Scientific operates across three core segments: Life Sciences, Optical Technologies, and Measurement and Control, catering to a broad range of scientific, industrial, and healthcare markets.
  • 4Research and development spending remained consistent in recent years, with $171.6 million in 2001, $176.8 million in 2000, and $171.1 million in 1999, highlighting a commitment to innovation.
  • 5The company experienced a decrease in overall order backlog from $556.4 million in 2000 to $432.6 million in 2001, primarily driven by slowdowns in the Optical Technologies and Measurement and Control sectors.
  • 6No single customer accounted for more than 10% of total revenues in the past three years, indicating a diversified customer base.
  • 7Environmental regulations are not expected to significantly impact capital spending, earnings, or competitive position.

Frequently Asked Questions

The company was in the process of completing a major reorganization, which involved taking private its publicly traded subsidiaries, divesting non-core businesses (over $1.5 billion in revenue), and spinning off certain business units like paper-recycling and medical products. This effort aimed to simplify the corporate structure and focus on core operations.

The company reports its business in three principal sectors: Life Sciences (serving biotechnology, pharmaceutical, and healthcare markets), Optical Technologies (focusing on optical and semiconductor equipment), and Measurement and Control (providing sensors, monitors, and control systems for industrial processes).

The strategy moving forward focuses on integrating operations for improved productivity and customer service. The company intends to drive growth through internal development, investing proceeds from business sales into high-growth market opportunities, and augmenting this with strategic acquisitions to expand its technological reach and market presence.

No, the filing states that no single customer accounted for more than 10% of total revenues in the past three years, indicating a diversified customer base and reducing concentration risk.